You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for GLIPIZIDE XL


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for GLIPIZIDE XL

Average Pharmacy Cost for GLIPIZIDE XL

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
GLIPIZIDE XL 10 MG TABLET 59762-0542-02 0.15035 EACH 2025-01-22
GLIPIZIDE XL 10 MG TABLET 59762-0542-02 0.14818 EACH 2024-12-18
GLIPIZIDE XL 10 MG TABLET 59762-0542-02 0.13342 EACH 2024-11-20
GLIPIZIDE XL 5 MG TABLET 59762-0541-02 0.08732 EACH 2024-10-23
GLIPIZIDE XL 10 MG TABLET 59762-0542-02 0.16178 EACH 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for GLIPIZIDE XL

Market Overview

GLIPIZIDE XL, a member of the sulfonylureas drug class, is widely used for managing type 2 diabetes by stimulating the pancreas to produce more insulin and helping the body use insulin more effectively. Here is a comprehensive analysis of the market and price projections for GLIPIZIDE XL.

Global Market Size and Growth

The global glipizide tablets market, which includes GLIPIZIDE XL, was valued at approximately USD 2.5 billion in 2023 and is projected to reach USD 4.3 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period from 2024 to 2033[3].

Market Drivers

Several factors are driving the growth of the glipizide tablets market:

  • Increasing Prevalence of Type 2 Diabetes: The rising incidence of type 2 diabetes, particularly in developing countries, is a primary driver. According to the International Diabetes Federation, an estimated 463 million adults worldwide had diabetes in 2019, and this number is expected to rise to 700 million by 2045[3].
  • Growing Geriatric Population: The risk of developing type 2 diabetes increases with age, and the growing geriatric population is propelling market growth.
  • Expanding Healthcare Infrastructure: Emerging markets, especially in Asia-Pacific and Latin America, have expanding healthcare infrastructure and growing awareness about diabetes management, contributing to market growth[3].

Regional Analysis

The market for GLIPIZIDE XL is distributed across various regions:

  • North America: This is the largest market, driven by the high prevalence of type 2 diabetes, well-established healthcare infrastructure, and significant healthcare spending in the United States and Canada[3].
  • Europe: Europe is the second-largest market, with countries like Germany, France, and the United Kingdom being major contributors. The increasing awareness about diabetes management and reimbursement policies for antidiabetic treatments support market growth in this region[3].
  • Asia-Pacific: This region is expected to witness the highest growth rate during the forecast period, driven by a large patient population, improving healthcare infrastructure, and rising disposable incomes. Countries like China, India, and Japan are key markets in this region[3].

Price Projections and Affordability

The cost of GLIPIZIDE XL varies based on dosage and quantity:

  • 2.5 mg: Prices start from around $13.16 for 30 tablets, with a per-unit cost of $0.44[2].
  • 5 mg: Prices start from around $21.70 for 100 tablets, with a per-unit cost of $0.22[2].
  • 10 mg: Prices start from around $35.27 for 100 tablets, with a per-unit cost of $0.35[2].

Generic versions of glipizide are also available, which can significantly reduce the cost. For example, the cost for a generic glipizide 10 mg oral tablet can be around $12 for a supply of 14 tablets[5].

Discounts and Patient Assistance

To make GLIPIZIDE XL more affordable, several discount programs and patient assistance options are available:

  • Discount Cards: Programs like the Drugs.com Discount Card can save patients up to 80% or more off the cost of prescription medicines[2][5].
  • Copay Cards: These cards can help reduce the out-of-pocket costs for patients.
  • Patient Assistance Programs: Various pharmaceutical companies and non-profit organizations offer patient assistance programs to help patients access necessary medications at a lower cost[2].

Challenges and Opportunities

Despite the growth potential, the market faces several challenges:

  • Alternative Oral Antidiabetic Drugs: The availability of newer oral antidiabetic agents can pose competition to GLIPIZIDE XL.
  • Potential Side Effects: Sulfonylureas, including GLIPIZIDE XL, can have side effects such as hypoglycemia, dizziness, and gastrointestinal reactions, which may deter some patients[4].

However, there are also opportunities for growth:

  • Emerging Markets: Developing countries offer significant growth opportunities due to their large patient populations and expanding healthcare infrastructure.
  • Fixed-Dose Combinations: Developing fixed-dose combinations containing glipizide and other oral antidiabetic agents can improve patient compliance and glycemic control.
  • Extended-Release Formulations: Improving the convenience of dosing and reducing the risk of hypoglycemia through advanced formulations can enhance market appeal[3].

Future Outlook

The glipizide tablets market, including GLIPIZIDE XL, is expected to experience steady growth driven by the increasing prevalence of type 2 diabetes and the rising geriatric population. The market will benefit from expanding healthcare infrastructure and growing awareness about diabetes management in emerging economies. However, manufacturers will need to focus on developing advanced formulations, exploring fixed-dose combinations, and strengthening their presence in emerging markets to maintain growth[3].

Key Takeaways

  • The global glipizide tablets market is projected to grow at a CAGR of 5.3% from 2024 to 2033.
  • The market is driven by the increasing prevalence of type 2 diabetes and the growing geriatric population.
  • North America and Europe are significant markets, with the Asia-Pacific region expected to witness the highest growth rate.
  • Prices for GLIPIZIDE XL vary based on dosage and quantity, with generic versions offering cost savings.
  • Discount programs and patient assistance options are available to make the medication more affordable.
  • The market faces challenges from alternative oral antidiabetic drugs and potential side effects but offers opportunities in emerging markets and through advanced formulations.

FAQs

1. What is the primary use of GLIPIZIDE XL? GLIPIZIDE XL is used to control blood sugar levels in patients with type 2 diabetes by stimulating the pancreas to produce more insulin and helping the body use insulin more effectively.

2. What is the projected growth rate of the glipizide tablets market? The glipizide tablets market is projected to grow at a CAGR of 5.3% from 2024 to 2033[3].

3. Which regions are the largest markets for GLIPIZIDE XL? North America is the largest market, followed by Europe, with the Asia-Pacific region expected to witness the highest growth rate[3].

4. How much does GLIPIZIDE XL typically cost? The cost of GLIPIZIDE XL varies, but for example, a 5 mg oral tablet can cost around $21.70 for 100 tablets, with a per-unit cost of $0.22[2].

5. Are there any discount programs available for GLIPIZIDE XL? Yes, discount programs like the Drugs.com Discount Card can save patients up to 80% or more off the cost of prescription medicines[2][5].

Cited Sources

  1. FDA Label for Glucotrol XL: AccessData FDA, "Glucotrol XL" Label[1].
  2. Drugs.com Price Guide for GlipiZIDE XL: Drugs.com, "GlipiZIDE XL Prices, Coupons, Copay Cards & Patient Assistance"[2].
  3. Data Horizon Research Report: Data Horizon Research, "Glipizide Tablets Market Size, Share, Growth, Statistics Report 2033"[3].
  4. FDA Label for GLUCOTROL XL (2021): AccessData FDA, "GLUCOTROL XL (glipizide) extended release tablets, for oral use" Label[4].
  5. Drugs.com Price Guide for Glipizide: Drugs.com, "Glipizide Prices, Coupons, Copay Cards & Patient Assistance"[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.